Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2006

View Archived Issues

De Novo enters drug discovery collaboration with Genzyme

Potent and selective AEA reuptake inhibitors as antispastics in MS

A.P. Pharma sells royalty rights to Retin-A Micro and Carac

New investment supports GammaCan's phase II study of GCAN-101

BioVeris signs option agreement with TheraCarb for C. albicans vaccine candidate

Merck Frosst presents a new potent, selective orally active cathepsin K inhibitor

Phase I study completed for KB-2115

Department of Defense grant for preclinical study of Tarvacin for prostate cancer

Positive phase III results for SPP-100 in hypertension

Shareholders vote in favor of Crucell's offer for Berna

NanoCarrier to conduct phase I study of Nanoplatin in U.K.

Tolamba shows clinical benefit in reducing symptoms of ragweed allergy

GdSSR: A novel putative approach for glioblastoma multiforme treatment

NovImmune files IND for antibody for autoimmune disease

EDP-420 begins North American phase II trial for CAP

Enrollment nearing completion in phase IIIb mesothelioma study of Onconase

Phase III development of Acapodene recommended to continue

Panzem studied in phase II for recurring GBM

Arteriocyte studies adult derived hemangioblasts to treat chronic ischemia

Procyon Biopharma and Cellpep to merge to form Ambrilia Biopharma

HPV-specific inhibitors from Boehringer Ingelheim as a gateway for future drug design

Novel agents imparted for inflammatory disorders

Taisho patent describes compounds with potential for the treatment for renal disorders, etc.

Recent patents cover novel treatments for psychological disorders

Neuroprotective effects of targeting IKK for stroke

New therapeutics for cancer covered in recent patent literature

SuperGen withdraws Orathecin MAA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...